Isomorphic Labs in Talks for Funding at Valuation Up to $50 Billion
Bloomberg exclusively reported that Isomorphic Labs, an AI drug discovery company spun out of Google DeepMind, is in early talks for a new funding round at a valuation of at least $40 billion, with subsequent reports suggesting the figure could reach roughly $50 billion. Negotiations remain at an early stage, and neither the amount nor the valuation has been finalized. This is one of the largest funding negotiations in AI-driven drug development to date and is worth watching closely.
Confirmed
- Isomorphic Labs was founded and is led by DeepMind CEO Demis Hassabis, focusing on AI-powered drug discovery with a mission to "cure all diseases"
- The company is an independent entity spun out of Google/Alphabet
- It is in early talks for a new funding round at a valuation of at least $40 billion, potentially up to around $50 billion
- The company plans to file its first Investigational New Drug (IND) application by the end of 2026
Not Yet Confirmed
- The funding amount, list of investors, and final valuation have not been disclosed; negotiations are still in early stages
Why It Matters
- If completed at a $40–50 billion valuation, it would be an unprecedented raise for AI drug discovery, reflecting strong capital-market bets on the "AI + pharma" space
- The valuation climbed from Bloomberg's initial report (at least $40 billion) to roughly $50 billion, signaling rising momentum in the talks
- The plan to submit its first IND by end of 2026 will be a key milestone for validating the commercial viability of Isomorphic Labs' AI drug discovery platform
2026-10-08 ~ 2026-10-08 · 6 related posts
Primary sources
- Isomorphic Labs in funding talks at $40B-plus valuation, possibly $50B — dinabass · 2026-10-08
- [source] Hassabis's Isomorphic Labs in talks to raise at ~$50 billion valuation — ns123abc · 2026-10-08
- [source] Isomorphic Labs in early talks to raise at $40B+ valuation, Bloomberg reports — nmasc_ · 2026-10-08